sodium-bicarbonate and Vascular-Diseases

sodium-bicarbonate has been researched along with Vascular-Diseases* in 2 studies

Trials

1 trial(s) available for sodium-bicarbonate and Vascular-Diseases

ArticleYear
Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, May-01, Volume: 79, Issue:6

    We compared use of intravenous (IV) normal saline (NS) to sodium bicarbonate (NaHCO(3)) with or without oral N-acetylcysteine (NAC) for prevention of contrast-induced acute kidney injury (CI-AKI).. CI-AKI is associated with significant adverse clinical events. Use of NAC has produced variable results. Recently, intravenous hydration with NaHCO(3) for CI-AKI prophylaxis has been adopted as standard treatment for patients with stable chronic renal disease undergoing catheterization procedures.. We prospectively enrolled 320 patients with baseline renal insufficiency scheduled to undergo catheterization. Patients were randomly assigned to receive either IV NS ± NAC (n = 161) or IV dextrose 5% in water containing 154 mEq/l of NaHCO(3) ± NAC (n = 159). IV NS was administered at 1 ml/kg body weight for 12 hr preprocedure and 12 more hr postprocedure. IV NaHCO(3) was administered at 3 ml/kg body weight for 1 hr preprocedure followed by 1 ml/kg body weight postprocedure. A 1,200 mg oral dose of NAC was given 2-12 hr preprocedure and 6-12 hr postprocedure in 50% of patients in each study arm. CI-AKI was defined as an increase of >0.5 mg/dl or >25% above baseline creatinine.. Overall incidence of CI-AKI was 10.3%. There was no significant difference in incidence among the two groups (NS ± NAC 11.8% vs. NaHCO(3) ± NAC 8.8%, p = ns). Incidence of CI-AKI increased with increasing age (p = 0.001), contrast agent use >3 ml/kg body weight (p = 0.038) and diuretic use (p = 0.005).. Incidence of CI-AKI was no different in the NaHCO(3) group compared to NS group, and NAC did not reduce CI-AKI in the two study arms.

    Topics: Acetylcysteine; Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Cardiac Catheterization; Catheterization, Peripheral; Chi-Square Distribution; Contrast Media; Coronary Angiography; Creatinine; Female; Fluid Therapy; Humans; Infusions, Intravenous; Kidney Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Renal Insufficiency; Risk Assessment; Risk Factors; Sodium Bicarbonate; Sodium Chloride; Time Factors; Treatment Outcome; Vascular Diseases; Wisconsin

2012

Other Studies

1 other study(ies) available for sodium-bicarbonate and Vascular-Diseases

ArticleYear
Calcification of superficial scalp veins secondary to intravenous infusion of sodium bicarbonate and calcium chloride.
    Cutis, 1983, Volume: 32, Issue:1

    Soft tissue calcification has been reported following the intramuscular injection of calcium salts and the intravenous administration of calcium gluconate. The present case report describes a neonate in whom calcification of the superficial scalp veins developed following administration of calcium chloride and sodium bicarbonate through a scalp vein needle.

    Topics: Bicarbonates; Calcinosis; Calcium Chloride; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infusions, Parenteral; Male; Scalp; Sodium Bicarbonate; Vascular Diseases; Veins

1983